1
|
Pappa E, Vavli E, Kostara C, Bairaktari E, Tsimihodimos V. HDL lipidomic analysis in patients with type 2 diabetes mellitus receiving fixed-dose combination of insulin degludec and liraglutide. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Pappa E, Arvaniti E, Dimou A, Kostara C, Tellis C, Tselepis A, Bairaktari E, Elisaf M, Tsimihodimos V. Effect Of The Fixed-Dose Combination Of Insulin Degludec And Liraglutide On Serum Lipoprotein Metabolism In Patients With Type 2 Diabetes Mellitus. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Skouroliakou M, Grosomanidis D, Massara P, Kostara C, Papandreou P, Ntountaniotis D, Xepapadakis G. Serum antioxidant capacity, biochemical profile and body composition of breast cancer survivors in a randomized Mediterranean dietary intervention study. Eur J Nutr 2017. [PMID: 28634625 DOI: 10.1007/s00394-017-1489-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
PURPOSE Increasing evidence suggests that Mediterranean Diet (MD) is correlated with reduced risk of breast cancer (BC) and cancer mortality, since it modifies patients' serum antioxidant capacity, body composition and biochemical parameters. The aim of the study was to investigate whether a dietary intervention based on MD has a beneficial effect on these factors. METHODS In this intervention study, seventy female BC survivors were randomly assigned to (1) the intervention group (personalized dietary intervention based on MD) and (2) the control group (received the updated American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention and ad libitum diet). Both groups were assessed twice [beginning, end of study (after 6 months)] regarding their anthropometric and biochemical parameters, serum vitamin C, vitamin A, a-tocopherol and CoQ10 levels, dietary intake and adherence to MD. An additional intermediate analysis was conducted on participants' body composition and biochemical profile. RESULTS Concerning the intervention group, body weight, body fat mass, waist circumference, body mass index as well as HDL-cholesterol were significantly decreased (P < 0.2%). An increase was observed in the vitamin C levels in blood (P < 0.2%). In the control group, body weight, body fat mass and serum total cholesterol rose (P < 0.2%). At the end of the study the two groups were significantly different considering blood glucose, vitamin C, polyunsaturated fatty acids, vitamin A and a-tocopherol levels. CONCLUSIONS This randomized dietary intervention based on MD managed to ameliorate serum antioxidant capacity, body composition, adherence to MD and glycemic profile of postmenopausal BC survivors.
Collapse
Affiliation(s)
- Maria Skouroliakou
- Department of Nutrition and Dietetics, Harokopio University of Athens, Kallithea, 17671, Athens, Greece.
| | | | - P Massara
- Department of Nutrition and Dietetics, Harokopio University of Athens, Kallithea, 17671, Athens, Greece
| | - C Kostara
- "IASO" Maternity Hospital, Marousi, 15123, Athens, Greece
| | - P Papandreou
- "IASO" Maternity Hospital, Marousi, 15123, Athens, Greece
| | - D Ntountaniotis
- Department of Chemistry, National and Kapodistrian University of Athens, Zografou, 15771, Athens, Greece
| | | |
Collapse
|
4
|
Kostara C, Tsimihodimos V, Bairaktari E, Elisaf M. Influence of HDL-cholesterol levels on HDL particles lipid composition in healthy individuals. an NMR-based lipidomic study. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
5
|
Nita E, Kyratzopoulou E, Eliadis P, Makatsori D, Kostara C, Mitsioni A, Tsaousi C, Levidiotou S, Bairaktari E, Mamalaki A, Voulgari P. AB0342 Serum Transferrin Receptor Ratio to Serum Ferritin and Hepcidin Levels in the Differential Diagnosis of Anemia in Rheumatoid Arthritis Patients. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4411] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
6
|
Christogiannis L, Kostapanos M, Kostara C, Barkas F, Liontos A, Panagiotopoulou T, Bairaktari E, Elisaf M. Effects of combinations of valsartan with amlodipine or hydrochlorothiazide on renal function and proteinuria in hypertensive patients with metabolic syndrome. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
7
|
Agouridis AP, Kostapanos MS, Tsimihodimos V, Kostara C, Mikhailidis DP, Bairaktari ET, Tselepis AD, Elisaf MS. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract 2012; 66:843-53. [PMID: 22897461 DOI: 10.1111/j.1742-1241.2012.02972.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND Raised triglycerides (TG), decreased high-density lipoprotein cholesterol (HDL-C) levels and a predominance of small dense low density lipoproteins (sdLDL) are characteristics of the metabolic syndrome (MetS). OBJECTIVE To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS. METHODS We previously randomised patients with low-density lipoprotein cholesterol (LDL-C) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day (R group, n = 30) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day (RF group, n = 30) or ω-3 fatty acids 2 g/day (Rω group, n = 30). In the present study, only patients with MetS were included (24, 23 and 24 in the R, RF and Rω groups respectively). At baseline and after 12 weeks of treatment, the lipoprotein subfraction profile was determined by polyacrylamide 3% gel electrophoresis. RESULTS The mean LDL size was significantly increased in all groups. This change was more prominent with RF than with other treatments in parallel with its greater hypotriglyceridemic capacity (p < 0.05 compared with R and Rω). A decrease in insulin resistance by RF was also noted. Only RF significantly raised HDL-C levels (by 7.7%, p < 0.05) by increasing the cholesterol of small HDL particles. The cholesterol of larger HDL subclasses was significantly increased by R and Rω. CONCLUSIONS All regimens increased mean LDL size; RF was the most effective. A differential effect of treatments was noted on the HDL subfraction profile.
Collapse
Affiliation(s)
- A P Agouridis
- Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Tzovaras V, Tsimihodimos V, Kostara C, Mitrogianni Z, Elisaf M. Aminoglycoside-induced nephrotoxicity studied by proton magnetic resonance spectroscopy of urine. Nephrol Dial Transplant 2011; 26:3219-3224. [DOI: 10.1093/ndt/gfr074] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
9
|
Rizos C, Milionis H, Kostapanos M, Florentin M, Kostara C, Elisaf M, Liberopoulos E. MS448 DIFFERENTIAL EFFECT OF SARTANS WITH VARIOUS PPARγ ACTIVATING CAPACITY COMBINED WITH ROSUVASTATIN ON GLUCOSE METABOLISM INDICES. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)70949-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
10
|
Nakou E, Filippatos T, Kostara C, Agouridis A, Bairaktari E, Elisaf M. P276 THE EFFECTS OF EZETIMIBE, ALONE OR COMBINED WITH ORLISTAT, ON TRIGLYCERIDE-RICH LIPOPROTEIN METABOLISM IN OVERWEIGHT AND OBESE PATIENTS WITH HYPERLIPIDAEMIA. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)70343-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
11
|
Filippatos T, Tsimihodimos V, Kostapanos M, Kostara C, Tzallas C, Bairaktari E, Tselepis A, Elisaf M. Abstract: P933 APOLIPOPROTEINS C-II AND C-III AND SMALL DENSE LDL CHOLESTEROL LEVELS IN NON-DIABETIC OBESE SUBJECTS WITH METABOLIC SYNDROME. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71054-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Florentin M, Liberopoulos EN, Filippatos TD, Kostara C, Tselepis A, Mikhailidis DP, Elisaf M. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother 2009; 9:2741-50. [PMID: 18937609 DOI: 10.1517/14656566.9.16.2741] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To assess the effect of rimonabant, micronised fenofibrate and their combination on anthropometric and metabolic parameters in overweight/obese patients with dyslipidaemia. METHODS All patients (n = 30) received a hypocaloric diet ( approximately 600 kcal/day deficit) and were randomly allocated to receive open-label rimonabant (R) 20 mg/day (n = 10), micronised fenofibrate (F) 200 mg/day (n = 10) or rimonabant 20 mg/day plus fenofibrate 200 mg/day (RF) (n = 10). Anthropometric and metabolic parameters were assessed at baseline and 3 months after treatment initiation. RESULTS Compared with baseline similar significant reductions in body weight, body mass index and waist circumference were observed in the R (-6, -5 and -5%, respectively; p < 0.01) and RF group (-5% for all, p < 0.05), while improvements in these parameters were smaller in the F group (-2, -2.5 and -2%, respectively; p < 0.05). Triglycerides were reduced by 18% in the R group (p = NS), by 39% in the F group (p < 0.001) and by 46% in the RF group (p < 0.05). Importantly, combination treatment resulted in a 42% increase in high-density lipoprotein cholesterol (HDL-C) levels (p < 0.05), while HDL-C was not significantly altered in the two monotherapy groups. Subsequently, a more pronounced increase in apolipoprotein A-I (ApoA-I) levels (+25%) was observed in the RF group compared with changes in both monotherapy groups (p < 0.0001 vs R and p < 0.005 vs F group). Low-density lipoprotein cholesterol (LDL-C) levels were not significantly altered in any group. Apolipoprotein B (apoB) levels were reduced in all groups and this reduction was significantly more pronounced in the RF group (p < 0.05 vs baseline as well as p < 0.005 and p < 0.01 for RF vs R and F groups, respectively). ApoB/apoA-I ratio decreased by 3% with R (p = NS), by 18% with F (p < 0.05) and by 40% with RF treatment (p < 0.01). Total cholesterol to HDL-C ratio decreased by 20% with F (p < 0.0001) and by 33% with RF therapy (p < 0.005), while it was not significantly altered in R group. CONCLUSION The combination of rimonabant and fenofibrate may further improve metabolic parameters in overweight/obese patients with dyslipidaemia compared with each monotherapy. This improvement is particularly pronounced for HDL-C levels.
Collapse
Affiliation(s)
- M Florentin
- University of Ioannina, Medical School, Department of Internal Medicine, 45110, Ioannina, Greece
| | | | | | | | | | | | | |
Collapse
|
13
|
Kalogirou M, Tsimihodimos V, Gazi I, Kostara C, Tselepis A, Elisaf M. PO23-726 EFFECT OF EZETIMIBE ON LIPOPROTEIN SUBFRACTIONS IN PATIENTS WITH PRIMARY DYSLIPIDEMIAS. ATHEROSCLEROSIS SUPP 2007. [DOI: 10.1016/s1567-5688(07)71736-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Kostapanos M, Filippatos T, Milionis H, Kostara C, Bairaktari E, Elisaf M. Th-P16:404 Effect of rosuvastatin on apolipoprotein CII and CIII serum levels in patients with primary dyslipidemia. ATHEROSCLEROSIS SUPP 2006. [DOI: 10.1016/s1567-5688(06)82362-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
15
|
Gazi I, Filippatos T, Bairaktari E, Kostara C, Tselepis A, Elisaf M. We-P11:104 LDL subfractions in patients with metabolic syndrome. ATHEROSCLEROSIS SUPP 2006. [DOI: 10.1016/s1567-5688(06)81458-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|